Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2019Transplantation

Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor–Specific Antibodies

View Full Paper
Ask AI
Bookmark
Share

Authors

SDScott DavisRegulus Therapeutics (United States)JGJane GrallaUniversity of Colorado Anschutz Medical CampusPKPatrick KlemUniversity of Colorado Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Davis et al. (2019) studied this question.

synapsesocial.com/papers/6aa44cc346cf29262817f5e6https://doi.org/10.1097/tp.0000000000002913
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development2017 · 279 citations
  2. 2A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy1993 · 2,078 citations
  3. 3Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development2015 · 205 citations
  4. 4Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts2013 · 372 citations
  5. 5Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions2014 · 1,353 citations